Elevation of GLP-1 in Diabetes Guidelines: From Glucose-Lowering Alone to Comprehensive Clinical Benefits

In recent years, treatment guidelines for type 2 diabetes mellitus (T2DM) have been continuously updated worldwide. One of the most notable changes is the significant rise in the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

In the past, the primary goal of diabetes treatment was mainly focused on controlling blood glucose levels. However, with the accumulation of large-scale clinical evidence, the medical community has increasingly recognized that glucose lowering alone is not sufficient to improve long-term patient outcomes. Cardiovascular disease, chronic kidney disease, and obesity-related complications are now understood to be key factors affecting both quality of life and survival in patients.

During this transformation in treatment philosophy, global pharmaceutical distributor DengYueMed has been continuously providing international patients and healthcare institutions with access to innovative medicines and information support, enabling advanced therapeutic options to reach clinical settings more efficiently.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by the intestines after food intake.

GLP-1 receptor agonists mimic the action of endogenous GLP-1 and primarily work through the following mechanisms:

● Stimulating glucose-dependent insulin secretion

● Suppressing glucagon secretion

● Delaying gastric emptying

● Increasing satiety

● Reducing appetite and energy intakeBecause of its glucose-dependent mechanism of action, the risk of hypoglycemia is significantly lower compared to sulfonylureas and insulin.

Why Has Diabetes Treatment Philosophy Changed?

For decades, diabetes treatment has typically followed a fixed pathway:

Lifestyle intervention → Metformin → Combination oral therapy → Insulin

However, extensive research has shown that even when glycemic targets are achieved, patients still face a relatively high risk of:

● Myocardial infarction

● Stroke

● Heart failure

● Progression of chronic kidney disease

● All-cause mortalityTherefore, current international guidelines increasingly emphasize a shift:

From “glucose-centered control” to “patient-outcome-centered care”

The new treatment goals include:

● Glycemic control

● Weight reduction

● Cardiovascular protection

● Slowing kidney disease progression

● Improving quality of life

● Reducing mortality riskGLP-1 receptor agonists are well aligned with this evolving treatment paradigm.

Increasing Role of GLP-1 in International Guidelines

Changes in the ADA Guidelines

In recent years, the American Diabetes Association has continuously elevated the recommendation level of GLP-1 RAs in its “Standards of Care in Diabetes”.

For patients with:

● Atherosclerotic cardiovascular disease (ASCVD)

● High cardiovascular risk

● Obesity or overweight

● Chronic kidney disease (CKD)GLP-1 RAs may be considered a preferred therapeutic option, rather than being limited to second-line therapy.

This indicates that GLP-1 RAs are no longer merely “second-line glucose-lowering drugs.”

Updates from EASD Consensus

The European Association for the Study of Diabetes and ADA joint consensus further emphasizes that treatment strategies should be individualized based on comorbid risks.

For patients with obesity and cardiovascular risk:

GLP-1 RAs may even be considered as part of initial combination therapy alongside metformin.

Why Do GLP-1 Drugs Gain Guideline Preference?

1. Strong Glucose-Lowering Effect

Most GLP-1 RAs reduce HbA1c by approximately 1%–2%.

Some newer agents may achieve even greater reductions.

Representative drugs include:

● Liraglutide

● Semaglutide

● Dulaglutide

● Exenatide

● Benaglutide

2. Significant Weight Loss Effect

Obesity is closely associated with type 2 diabetes.

GLP-1 RAs act on central nervous system appetite regulation pathways, helping patients reduce caloric intake.

Studies have shown:

Semaglutide can achieve more than 10% weight reduction in some patients.

New-generation drugs such as tirzepatide can achieve 15%–20% or more weight loss.

This benefit is particularly important for patients with obesity-related diabetes.

3. Cardiovascular Protection

This is one of the key reasons for the rising status of GLP-1 RAs.

Multiple large cardiovascular outcome trials (CVOTs) have confirmed:

1.  Liraglutide

2.  The LEADER trial demonstrated a reduction in major adverse cardiovascular events (MACE).Semaglutide

3.  The SUSTAIN-6 trial showed a reduction in cardiovascular events.Dulaglutide

The REWIND trial demonstrated long-term cardiovascular benefit even in earlier-stage diabetes.These findings have elevated GLP-1 RAs from glucose-lowering agents to cardiovascular protective therapies.

4. Renal Protective Effects

Diabetic kidney disease is a leading cause of end-stage renal disease.

Studies suggest that GLP-1 RAs can:

● Reduce urinary albumin levels

● Slow decline in kidney function

● Reduce renal outcome eventsFor patients with chronic kidney disease, GLP-1 RAs combined with SGLT-2 inhibitors are becoming an important therapeutic strategy.

Key Representative GLP-1 Drugs

Semaglutide

This class of drugs is currently one of the most widely used GLP-1 receptor agonists in clinical practice, with the following characteristics:

● Once-weekly administration, improving treatment adherence

● Strong glucose-lowering effect (significant HbA1c reduction)

● Significant weight loss effects in patients with obesity or overweight

● Proven cardiovascular benefits confirmed by multiple large-scale clinical trials

Due to its comprehensive advantages in glycemic control, weight reduction, and cardiovascular protection, this class of drugs has become one of the core therapeutic options in the management of metabolic diseases.

Liraglutide

As one of the earlier GLP-1 receptor agonists used in clinical practice, this drug has accumulated extensive evidence from long-term studies and real-world use:

● Once-daily administration with well-established clinical experience

● Strong evidence of cardiovascular benefit, particularly suitable for high-risk patients

● Stable efficacy in both glycemic control and weight management

● Well-established safety profile with broad patient applicability

This drug holds important clinical value in patients with type 2 diabetes who are at high cardiovascular risk.

Dulaglutide

This drug is widely used in long-term management of type 2 diabetes in a long-acting formulation:

● Once-weekly administration, convenient to use

● Helps improve long-term treatment adherence

● Demonstrates favorable trends in cardiovascular outcomes in real-world studies

● Well-established long-term safety and tolerability data

Its “long-acting + stable” profile makes it highly valuable in chronic disease management.

Tirzepatide

This drug belongs to a new generation of incretin-based therapies with a dual-target mechanism:

● Acts on both GIP and GLP-1 receptors simultaneously

● Shows stronger improvements in glycemic control

● Demonstrates superior weight reduction compared with most traditional GLP-1 receptor agonists

● Considered an important direction in the future development of metabolic disease therapy

Due to its unique mechanism, this class of drugs is widely regarded as an important next-generation upgrade in the treatment of diabetes and obesity.

What Does the GLP-1 Era Mean?

The rise of GLP-1 RAs reflects a fundamental shift in diabetes management.

In the past, the focus was on glucose numbers.

Now, the focus is on overall patient health outcomes.

When selecting therapy, clinicians no longer consider HbA1c alone, but also:

● Weight management

● Cardiovascular risk

● Renal protection

● Long-term prognosis

● Quality of lifeIn this context, GLP-1 receptor agonists have evolved from traditional glucose-lowering drugs into essential tools for comprehensive metabolic disease management.

Conclusion

With increasing clinical evidence, GLP-1 receptor agonists are reshaping the global treatment landscape for type 2 diabetes. Their benefits extend beyond glucose control to weight reduction, cardiovascular protection, and renal benefits, and their recommendation level in international guidelines continues to rise, marking an inevitable trend.

In the future, with the widespread adoption of innovative therapies such as semaglutide and tirzepatide, diabetes management will progressively enter a new era centered on long-term patient outcomes.

In this global transformation of healthcare, global pharmaceutical distributor DengYueMed will continue to play a key role in improving drug accessibility and cross-border healthcare services, helping bring innovative treatments to patients worldwide more efficiently.